Joseph Liechty, MD
Vascular Surgery · Plano, TXNPI 1043416316
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 69.3% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $34,973 and has fallen 59.3% since, to $14,248 in 2025. Among vascular surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $307.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$65K
- Stryker$14K
- Medtronic$11K
- Teleflex LLC$700
- Endologix LLC$625
- Boston Scientific$404
- plus $2K from 29 others
What the payments were for
- Consulting fees$17,25019%
- Speaking & faculty fees$46,95050%
- Travel & lodging$17,85119%
- Food & beverage$11,04712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 130 | $64,553 |
| Stryker | 24 | $13,560 |
| Medtronic(2 entities) | 51 | $10,927 |
| Teleflex LLC | 1 | $700 |
| Endologix LLC | 5 | $625 |
| Boston Scientific | 19 | $404 |
| W. L. Gore & Associates, Inc. | 6 | $311 |
| Koya Medical, Inc. | 1 | $247 |
| Penumbra, Inc. | 2 | $241 |
| Terumo Medical Corporation | 7 | $237 |
| Tactile Systems Technology Inc | 13 | $230 |
| Truvic Medical, Inc. | 2 | $140 |
| Lemaitre Vascular, Inc. | 3 | $133 |
| Shockwave Medical, Inc | 3 | $98 |
| Imperative Care, Inc | 3 | $83 |
| Johnson & Johnson(2 entities) | 4 | $64 |
| Surmodics, Inc. | 3 | $60 |
| Abbott | 2 | $53 |
| Bard Peripheral Vascular, Inc. | 2 | $46 |
| Cvrx, Inc. | 2 | $45 |
| Angiodynamics, Inc. | 3 | $39 |
| Reflow Medical Inc | 2 | $38 |
| Biocompatibles, Inc. | 2 | $36 |
| Silk Road Medical, Inc. | 1 | $27 |
| Cardiovascular Systems Inc. | 2 | $27 |
| Axogen | 1 | $24 |
| Baxter Healthcare | 1 | $24 |
| Contego Medical, Inc | 1 | $19 |
| Pfizer | 1 | $17 |
| Inspiremd Ltd | 1 | $16 |
| Cook Medical LLC | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $15 |
| EKOS Corporation | 1 | $15 |
| Neuros Medical, Inc. | 1 | $14 |
| BD | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$76,489
- CT THROMBECTOMY SYSTEM KIT$74,860
- IN.PACT Admiral$9,768
- Dayspring$742
- MANTA$700
- Ovation$356
- Abre$287
- Koya Medical$247
- Torus Stent Graft System$205
- ENDOCROSS Device$205
- ARTIX MT$173
- CLOTTRIEVER BOLD CATHETER$144
- VIABAHN VBX Balloon Expandable Endoprosthesis$141
- ANGIO-SEAL$138
- METACROSS OTW$138
- GLIDESHEATH SLENDER$138
- RUBY Coil$122
- Indigo System$119
- GENERAL VASCULAR INTERVENTION$117
- VIABAHN Endoprosthesis with Heparin Bioactive Surface$115
How this compares
$93,098 in reported general payments places this provider in the 90th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $49,256 |
| Cilostazol | 22 | $441 |
| ClopidogrelClopidogrel Bisulfate | 18 | $279 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $49,25659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 347 vascular surgery providers in Texas.
Other vascular surgery in Plano
- Gregory PearlDallas$2.3M
- Mazin FotehAustin$1.6M
- Alan LumsdenHouston$742K
- Stephen HohmannDallas$499K
- Michael SiahDallas$392K
- Gustavo OderichHouston$319K
- Jean BismuthHouston$243K
- Carlos TimaranDallas$231K
- Dennis GableDallas$211K
- Thomas LohShenandoah$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.